Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Remon

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 6, 2013
SEOM clinical guidelines for the treatment of small-cell lung cancer 2013M Dómine Gómez, T Morán Bueno, A Artal Cortés, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 19, 2021
Small cell lung cancer: a slightly less orphan disease after immunotherapyJ Remon, M Aldea, B Besse, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 27, 2012
Metastatic lymph node ratio versus number of metastatic lymph nodes as a prognostic factor in gastric cancerF Espín, A Bianchi, S Llorca, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2017
Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approachesJ Remon, N Pardo, A Martinez-Martí, et al.
Lung Cancer (Amsterdam, Netherlands)|February 6, 2018
Corrigendum to "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches" [Lung Cancer 106 (2017) 70-75]J Remon, N Pardo, A Martinez-Martí, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignanciesJ Remon, N Abedallaa, E Taranchon-Clermont, et al.
Revista Espanola De Enfermedades Digestivas|April 9, 2010
Large lymph node size harvested as prognostic factor in gastric cancer?Francisco Espín, A Bianchi, S Llorca, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 5, 2022
SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)J Remon, R Bernabé, P Diz, et al.
Lung Cancer (Amsterdam, Netherlands)|April 2, 2025
ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitorsS V Liu, R Dziadziuszko, S Viteri, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 27, 2013
Lung cancer in women: an overview with special focus on Spanish womenJ Remon, E Molina-Montes, M Majem, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 6, 2013
SEOM clinical guidelines for the treatment of small-cell lung cancer 2013M Dómine Gómez, T Morán Bueno, A Artal Cortés, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 19, 2021
Small cell lung cancer: a slightly less orphan disease after immunotherapyJ Remon, M Aldea, B Besse, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 27, 2012
Metastatic lymph node ratio versus number of metastatic lymph nodes as a prognostic factor in gastric cancerF Espín, A Bianchi, S Llorca, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2017
Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approachesJ Remon, N Pardo, A Martinez-Martí, et al.
Lung Cancer (Amsterdam, Netherlands)|February 6, 2018
Corrigendum to "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches" [Lung Cancer 106 (2017) 70-75]J Remon, N Pardo, A Martinez-Martí, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignanciesJ Remon, N Abedallaa, E Taranchon-Clermont, et al.
Revista Espanola De Enfermedades Digestivas|April 9, 2010
Large lymph node size harvested as prognostic factor in gastric cancer?Francisco Espín, A Bianchi, S Llorca, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 5, 2022
SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)J Remon, R Bernabé, P Diz, et al.
Lung Cancer (Amsterdam, Netherlands)|April 2, 2025
ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitorsS V Liu, R Dziadziuszko, S Viteri, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 27, 2013
Lung cancer in women: an overview with special focus on Spanish womenJ Remon, E Molina-Montes, M Majem, et al.
Pageof 6